Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1654
    -0.0029 (-0.25%)
     

  • GBP/USD

    1.2548
    +0.0015 (+0.12%)
     

  • Bitcoin GBP

    49,260.25
    +1,970.55 (+4.17%)
     

  • CMC Crypto 200

    1,340.55
    +63.57 (+4.98%)
     

  • S&P 500

    5,130.96
    +66.76 (+1.32%)
     

  • DOW

    38,694.50
    +468.84 (+1.23%)
     

  • CRUDE OIL

    78.09
    -0.86 (-1.09%)
     

  • GOLD FUTURES

    2,307.40
    -2.20 (-0.10%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

Merck says it has agreed to supply potential COVID-19 drug Rebif to EU countries

Reuters
·1-min read

FRANKFURT (Reuters) - German drugmaker Merck <MRCG.DE> said on Wednesday it had agreed to supply its potential COVID-19 drug Rebif to European Union countries should orders be placed for the treatment.

The comment followed a Reuters report earlier on Wednesday about a deal reached by the EU Commission and Merck for the supply of Rebif. A similar deal was struck with Roche <ROG.S> about possible COVID-19 treatment RoActemra.

"Merck has been asked by the European Commission to be prepared to supply one of its medicines, Rebif (Interferon beta-1a), to EU countries upon request if and when the indication for COVID-19 treatment is adjudicated," the company said in a statement to Reuters.

Rebif is currently used for the treatment of relapsing multiple sclerosis and is being tested as a possible therapy for COVID-19 patients.

(Reporting by Patricia Weiss in Frankfurt; writing by Francesco Guarasco. Editing by Jane Merriman)